Silas Inman

The PD-L1 inhibitor avelumab demonstrated durable responses and promising early survival data for patients with pretreated metastatic Merkel cell carcinoma.

The combination of dabrafenib and trametinib continued to demonstrate impressive overall survival and progression-free survival findings for patients with BRAF-mutant metastatic melanoma in 3-year follow-up data from the phase III COMBI-d study.

The MEK inhibitor binimetinib reduced the risk of progression or death by 38% compared with dacarbazine in patients with NRAS-mutant metastatic melanoma.

Treatment with single-agent nivolumab improved overall survival and objective response rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

The combination of dabrafenib and trametinib was highly effective as a treatment for patients with BRAF V600E-mutant non–small cell lung cancer.

Treatment with rovalpituzumab tesirine demonstrated single-agent activity and a manageable safety profile for patients with recurrent/refractory small cell lung cancer.

Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.

The combination of the 4-1BB agonist utomilumab and the PD-1 inhibitor pembrolizumab was safe and effective as a treatment for patients with advanced solid tumors.

Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.

Treatment with the combination of nivolumab and ipilimumab demonstrated a median overall survival of 7.7 months and a 1-year OS rate of 43% for patients with recurrent small cell lung cancer.

The anti-CD38 monoclonal antibody isatuximab showed promising signs of activity as a single-agent for patients with heavily pretreated relapsed/refractory multiple myeloma.

The FDA has approved new diagnostic tests for the detection of somatostatin receptor-positive neuroendocrine tumors and for EGFR mutations from blood samples for patients with non–small cell lung cancer.

Frontline treatment with fulvestrant improved progression-free survival versus anastrozole for postmenopausal patients with locally-advanced or metastatic HR-positive breast cancer.

Outcomes were significantly better in clinical trials that utilized a biomarker-based treatment selection strategy compared with non-personalized approaches.

The combination of the CDK4/6 inhibitor ribociclib and letrozole significantly improved progression-free survival compared with letrozole alone for patients with HR-positive, HER2-negative advanced breast cancer.

A phase III study exploring the combination of olaparib and paclitaxel missed its primary endpoint of improvement in overall survival compared with paclitaxel and placebo for patients with advanced gastric cancer.

The recombinant oncolytic poliovirus PVS-RIPO has received breakthrough therapy designation from the FDA as a potential treatment for patients with recurrent glioblastoma multiforme.

The FDA has approved the combination of lenvatinib and everolimus as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy

The European Commission has approved the combination of ipilimumab and nivolumab as a treatment for patients with unresectable or metastatic melanoma regardless of BRAF status.

The Committee for Medicinal Products for Human Use has recommended the first-line approval of bevacizumab (Avastin) in combination with erlotinib (Tarceva) for patients with advanced or metastatic EGFR-mutant non–small cell lung cancer.

The Committee for Medicinal Products for Human Use has recommended the frontline approval for ibrutinib (Imbruvica) as a single-agent for patients with chronic lymphocytic leukemia.

Adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression or death by 26% compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.

The FDA has granted a breakthrough therapy designation to nivolumab as a single-agent treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck following a platinum-based therapy.

The phase III PALOMA-2 trial has shown a significant improvement in progression-free survival for the frontline combination of palbociclib and letrozole compared letrozole alone for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

The FDA has granted a breakthrough therapy designation to pembrolizumab as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma.

Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma who had not received prior ipilimumab.

Plasma-based genetic testing can effectively be used to determine whether a tissue biopsy is necessary for EGFR mutation analysis in patients with non–small cell lung cancer.

The FDA has granted a priority review designation to pembrolizumab (Keytruda) as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.